A5047272233- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Pancreatic and Hepatic Oncology Research
- RNA modifications and cancer
- CAR-T cell therapy research
- Genetic factors in colorectal cancer
- Multiple Myeloma Research and Treatments
- Lung Cancer Research Studies
- DNA Repair Mechanisms
- Childhood Cancer Survivors' Quality of Life
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Cancer Genomics and Diagnostics
- Neuroendocrine Tumor Research Advances
University Hospital Schleswig-Holstein
2023-2024
University of Lübeck
2023-2024
Deutsche Forschungsgemeinschaft
2023-2024
Clinical Research Center Kiel
2023
University Medical Center
2023
University Children's Hospital Zurich
2020-2022
Orthopädische Universitätsklinik
2021
Charité - Universitätsmedizin Berlin
2020-2021
Humboldt-Universität zu Berlin
2020
Freie Universität Berlin
2020
Current classifications (World Health Organization-HAEM5/ICC) define up to 26 molecular B-cell precursor acute lymphoblastic leukemia (BCP-ALL) disease subtypes by genomic driver aberrations and corresponding gene expression signatures. Identification of transcriptome sequencing (RNA-Seq) is well established, while systematic approaches for analysis are less advanced. Therefore, we developed ALLCatchR, a machine learning-based classifier using RNA-Seq data allocate BCP-ALL samples all 21...
Abstract Distinct diagnostic entities within BCR::ABL1-positive acute lymphoblastic leukemia (ALL) are currently defined by the International Consensus Classification of myeloid neoplasms and leukemias (ICC): “lymphoid only”, with BCR::ABL1 observed exclusively in lymphatic precursors, vs “multilineage”, where is also present other hematopoietic lineages. Here, we analyzed transcriptomes 327 patients ALL (age, 2-84 years; median, 46 years) identified 2 main gene expression clusters...
Abstract Most relapses of acute lymphoblastic leukemia (ALL) occur in patients with a medium risk (MR) for relapse on the Associazione Italiana di Ematologia e Oncologia Pediatrica and Berlin-Frankfurt-Münster (AIEOP-BFM) ALL protocol, based persistence minimal residual disease (MRD). New insights into biological features that are associated MRD needed. Here, we identify glycosylphosphatidylinositol-anchored cell surface protein vanin-2 (VNN2; GPI-80) by charting proteome very high-risk (HR)...
Abstract Current classifications (WHO-HAEM5 / ICC) define up to 26 molecular B-cell precursor acute lymphoblastic leukemia (BCP-ALL) disease subtypes, which are defined by genomic driver aberrations and corresponding gene expression signatures. Identification of RNA-Seq is well established, while systematic approaches for analysis less advanced. Therefore, we developed ALLCatchR, a machine learning based classifier using data allocate BCP-ALL samples 21 subtypes. Trained on n=1,869...
Article23 November 2022Open Access Source DataTransparent process X-linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL Michela Carlet Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Center Environmental Health (HMGU), Munich, Germany Department Biotechnology and Food Engineering, MCI, The Entrepreneur School, Innsbruck, Austria Contribution: Conceptualization, Data curation, Formal analysis,...
Abstract Chemotherapy is curative for most children with acute lymphoblastic leukemia (ALL). Here we provide direct evidence that thiopurine chemotherapeutics can also directly induce drug resistance mutations leading to relapse. Using a large relapsed ALL cohort assembled from Chinese, US and German patients, found TP53 R248Q were highly enriched at relapse compared diagnosis. Relapse-specific was associated the acquisition of MMR deficiency in MSH2, MSH6, or PMS2 novel relapse-specific...